Alma íbúðafélag hf. Expands Bond Issuance with AL210926 Issue
PorAinvest
miércoles, 9 de julio de 2025, 11:53 am ET1 min de lectura
Alma íbúðafélag hf. has completed an expansion of its AL210926 bond issue, increasing the total amount to 3.1 million krónur. The bond has a floating interest rate tied to 3-month REIBOR rates with an additional 1.4% interest rate. The maturity date is September 21, 2026, and the issue is secured by general collateral. Acro verðbréf hf. managed the sale and listing of the bonds on Nasdaq Iceland hf.
Embla Medical hf. (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, has recently announced transactions in relation to its ongoing share buyback program. The program, initiated on February 7, 2025, aims to reduce the company’s share capital and adjust its capital structure by distributing capital to shareholders [1].During the period from June 30 to July 4, 2025, Embla Medical acquired 46,300 shares under the program at an average price of DKK 33.98. The transactions were conducted over five days, with the following details:
- June 30, 2025: 11,500 shares purchased at DKK 33.95
- July 1, 2025: 10,500 shares purchased at DKK 34.00
- July 2, 2025: 9,500 shares purchased at DKK 33.99
- July 3, 2025: 7,400 shares purchased at DKK 34.00
- July 4, 2025: 7,400 shares purchased at DKK 33.99
The total transaction value amounted to DKK 1,573,430. Following these acquisitions, Embla Medical holds 1,659,724 shares, representing 0.39% of the company’s total share capital [1].
The share buyback program is designed to conclude no later than December 31, 2025, but the company has the option to discontinue it at any time. Embla Medical is authorized to purchase up to 2,000,000 shares under the program, corresponding to 0.47% of the current share capital. The total consideration for shares purchased under the program shall not exceed USD 10 million [1].
The program is conducted in accordance with Regulation No. 596/2014 of the European Parliament and of the Council on market abuse ("MAR"), and the Commission’s delegated regulation 2016/1052 [1].
In a separate development, Alma íbúðafélag hf. has completed an expansion of its AL210926 bond issue, increasing the total amount to 3.1 million krónur. The bond features a floating interest rate tied to 3-month REIBOR rates with an additional 1.4% interest rate. The maturity date is September 21, 2026, and the issue is secured by general collateral. Acro verðbréf hf. managed the sale and listing of the bonds on Nasdaq Iceland hf. [2].
References:
[1] https://www.tradingview.com/news/reuters.com,2025-07-07:newsml_Wkr1qnhZF:0-embla-medical-hf-transactions-in-relation-to-share-buyback-program/
[2] https://news.cision.com/embla-medical-hf-/r/embla-medical-hf--transactions-in-relation-to-share-buyback-program%2Cc4204160

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema



Comentarios
Aún no hay comentarios